ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA October 2, 2019
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019 September 26, 2019
ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance August 28, 2019
ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data June 17, 2019
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296 June 6, 2019
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium June 3, 2019
